Scholarlink

<p>This study explores the role of adipogenesis-related genes (ARGs) in breast cancer, focusing on CEBPD, a key gene linked to adipogenesis. Using the TCGA-BRCA dataset, differentially expressed ARGs (DARGs) were identified, revealing 26 upregulated and 57 downregulated genes. CEBPD emerged as a central prognostic gene, exhibiting significantly lower expression in tumor tissues, which correlated with poor survival outcomes, making it an independent prognostic indicator. A nomogram integrating CEBPD expression was developed to predict 1-year, 3-year, and 5-year survival with moderate accuracy. Functional validation in vitro confirmed that CEBPD expression was downregulated at mRNA levels in breast cancer. Enforced overexpression of CEBPD significantly suppressed cancer cell proliferation. Gene Set Variation Analysis (GSVA) highlighted significant associations between CEBPD and biological processes such as angiogenesis, apoptosis, hypoxia, and inflammation. Immune microenvironment analysis showed distinct patterns of immune cell infiltration based on CEBPD expression levels. Overall, CEBPD significantly influences breast cancer progression and patient prognosis, suggesting its potential as a biomarker for therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The adipogenesis-related gene CEBPD as a prognostic biomarker and functional tumor suppressor in breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Shuang Qiu,
  • Xin Chen,
  • Jinyu Yang,
  • Yu Sun,
  • Yuanyuan Liu,
  • Di Wu,
  • Jianwei Sun

摘要

This study explores the role of adipogenesis-related genes (ARGs) in breast cancer, focusing on CEBPD, a key gene linked to adipogenesis. Using the TCGA-BRCA dataset, differentially expressed ARGs (DARGs) were identified, revealing 26 upregulated and 57 downregulated genes. CEBPD emerged as a central prognostic gene, exhibiting significantly lower expression in tumor tissues, which correlated with poor survival outcomes, making it an independent prognostic indicator. A nomogram integrating CEBPD expression was developed to predict 1-year, 3-year, and 5-year survival with moderate accuracy. Functional validation in vitro confirmed that CEBPD expression was downregulated at mRNA levels in breast cancer. Enforced overexpression of CEBPD significantly suppressed cancer cell proliferation. Gene Set Variation Analysis (GSVA) highlighted significant associations between CEBPD and biological processes such as angiogenesis, apoptosis, hypoxia, and inflammation. Immune microenvironment analysis showed distinct patterns of immune cell infiltration based on CEBPD expression levels. Overall, CEBPD significantly influences breast cancer progression and patient prognosis, suggesting its potential as a biomarker for therapeutic strategies.